In reply: I would like to respond to the letter by Kennedy et al regarding the passive transfer of human T-lymphotropic virus (HTLV) antibodies following Octagam (intravenous immunoglobulin [IVIg]) administration.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Government Department of Health and Ageing. Therapeutic Goods Administration. Standards for blood components. Therapeutic Goods Order No. 74. 2006. http://www.tga.gov.au/docs/html/tgo/tgo74.htm (accessed Mar 2007).
- 2. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 11th ed. January 2005. Strasbourg: Council of Europe Publishing, 2005.
- 3. US Food and Drug Administration. Code of Federal Regulations, Title 21, Part 610, Subpart E. Testing requirements for communicable disease agents (4-1-04 edition). Rockville, Md: FDA, 2004.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Octapharma is the manufacturer of Octagam. I am employed by Octapharma in the role of International Medical Director.